By Matthew Herper, Forbes Staff In a deal that could have a big impact on the future of DNA sequencing technology, lab equipment Thermo Fisher Scientific is buying rival Life Technologies for $13.6 billion in cash and the assumption of $2.2 billion in debt. The deal values Life shares at $76 per share. That’s more than many industry analysts expected the company could get in a sale.
Tag Archives: Thermo Fisher Scientific
And the Bidding War Winner Is …
By David Williamson, The Motley Fool
Filed under: Investing
Shares of Life Technologies jumped in January, when the company announced it was looking for a potential buyer, and it may now be close to a decision, with solid offers having come in both from Blackstone Group and Thermo Fisher Scientific . What will this biotech decide, and how will it affect investors? In this video, Motley Fool health-care analyst David Williamson gives us a breakdown of the offers on the table, and how investors could be affected depending on the outcome.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool‘s free report “
3 Stocks That Will Help You Retire Rich
” names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.
Click here now
to keep reading.
The article And the Bidding War Winner Is … originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Illumina and Thermo Fisher Scientific. Try any of our Foolish newsletter services free for 30 days. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");
function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
}
}
addEvent(window, "load", function(){new FoolVisualSciences();})
addEvent(window, "load", function(){new PickAd();})
var themeName = 'dailyfinance.com';
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-24928199-1']);
_gaq.push(['_trackPageview']);
(function () {
var ga = document.createElement('script');
ga.type = 'text/javascript';
Source: FULL ARTICLE at DailyFinance
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2013
By Business Wirevia The Motley Fool
Filed under: Investing
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2013
WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYS: TMO) , the world leader in serving science, announced that it will release its financial results for the first quarter 2013 before the market opens on Wednesday, April 24, 2013, and will hold a conference call on the same day at 8:30 a.m. EDT.
During the call, the company will discuss its first quarter financial performance, as well as future expectations. To listen, call (866) 804-6922 within the U.S. or (857) 350-1668 outside the U.S. and use conference ID 27442368. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com. The earnings press release and related information can be found in that section of our website under “Financial Results.” A replay of the call will be available under “Webcasts and Presentations” through Friday, May 17, 2013.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYS: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenue of $13 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com.
Thermo Fisher Scientific Inc.
Media Contact Information:
Ron O’Brien, 781-622-1242
ron.obrien@thermofisher.com
www.thermofisher.com
or
Investor Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS:
The article Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2013 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. …read more
Source: FULL ARTICLE at DailyFinance
1 of These 3 Stocks Won't Hold Its Gains
By Rich Duprey, The Motley Fool
Filed under: Investing
The decision by the European Union over the weekend to force Cypriot bank account holders to have their savings taxed in exchange for giving the nation’s government a bailout — and the resulting vote by Cyprus‘ parliament rejecting the deal — had a chilling impact on the market. The Dow Jones Industrial Average barely moved on Tuesday, inching up just 3 points, as all eyes wondered how the financial mess would sort itself out.
If Cyprus is allowed to leave the EU, the entire structure crumbles, but taxing the bank accounts of individuals is an unprecedented maneuver that could cause bank runs in other financial unstable countries because the camel put its nose under the tent.
The three following stocks, however, were far removed from the scene of international intrigue, rising on their own merits. Yet resist the urge to high-five everyone in the cubicles next to you. Smart investors won’t celebrate until they know why their stock surged, because without a fundamental basis for the bounce, these stocks could just as quickly make the return trip down.
|
Company |
% Gain |
|---|---|
|
Pacific Biosciences |
15.4% |
|
NPS Pharmaceuticals |
9.3% |
|
8.2% |
What a life!
With a potential bidding war looming for Life Technologies as possible buyers from Roche to Thermo Fisher Scientific and Danaher join a slew of PE firms weighing bids, investors looked about to see what else might be on the table and found Pacific BioSciences of California a possible target.
Life is a genetic testing company whose advanced diagnostics and consistent cash flows are considered jewels worthy of owning. PacBio is a similarly situated DNA sequencing company whose tools for biological research, including its RS system, might also suddenly be of interest to buyers if they’re eventually shut out of Life Technologies.
Roche, for example, previously considered taking over Illumina but ultimately declined, noting there were alternatives on the market for gene-sequencing technology. Presumably one of those is Life Technologies, and certainly another would be PacBio, but until bids are received for the former, a possible valuation for the latter isn’t really possible.
Take two; they’re cheap
It wasn’t a possible buyout that had shares of NPS Pharmaceuticals rocketing higher yesterday, but rather the buying back of global rights to its short-bowel syndrome drug, Gattex, and the recombinant human parathyroid hormone 1-84 that had investors bidding up its shares.
For just $50 million, NPS bought out its European distribution partner Takeda Pharmaceuticals for something that is expected to have peak sales of $350 million in the U.S. alone, in addition to what it can garner abroad. Short-bowel syndrome occurs when much of the small intestine has to be removed and the body is unable to absorb as much water and nutrients as it did previously.
NPS will pay Takeda an additional $30 million in cash or stock when sales of Gattex and 1-84 exceed $750 million annually.
Feeling sick
The …read more
Source: FULL ARTICLE at DailyFinance
Thermo Fisher Scientific Breaks New Ground to Drive Customer Innovation and Productivity
By Business Wirevia The Motley Fool
Filed under: Investing
Thermo Fisher Scientific Breaks New Ground to Drive Customer Innovation and Productivity
Unlocking Knowledge through Integrated Software, Instruments and Services
PHILADELPHIA–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYS: TMO) , the world leader in serving science, today announced that it is launching significant innovations in software, instruments, consumables and services that unify its industry-leading analytical instrument platforms and enable customers to turn data into knowledge faster and more reliably.
“We’re pleased to extend our legacy of developing the most powerful analytical tools in the industry,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “Especially significant this year is that we’re helping our customers to better leverage that power by launching new software systems to make it easier for them to turn data into valuable knowledge. By unifying instrument platforms on a single data system, we are helping our customers to analyze information more quickly, speeding results and accelerating the pace of discovery and applied science.”
During the annual Pittsburgh Conference and Exhibition, Thermo Fisher is showcasing advancements in laboratory software alongside new instruments and consumables for uses ranging from life sciences discovery to food and water quality. The company will highlight how it fulfills its mission – to enable its customers to make the world healthier, cleaner and safer – through the capabilities of its three premier brands: Thermo Scientific (Booth 1835), Fisher Scientificand Unity Lab Services (Booths 1924 and 1925). Pittcon is being held from March 17-21 at the Philadelphia Convention Center.
Turning Laboratory Data to Knowledge
Pittcon marks the global release of Thermo ScientificChromeleon™ ver. 7.2software, a milestone upgrade of the gold standard in chromatography data systems. For the first time, Chromeleon 7.2 unites mass spectrometry and chromatography instruments. Chromeleon software now supports Thermo Scientific mass spectrometers, including the ISQ single-quadrupole GC-MS and the TSQ-8000 GC-MS/MS. It also allows instruments to be integrated on enterprise-wide networks, making it the ideal solution for large universities and pharmaceutical researchers to facilitate collaboration between labs.
To further optimize laboratory assets, Thermo Fisher also introduces Unity Lab SmartCapture Asset Utilization Monitoring for automated support, service and maintenance, regardless of the instrument manufacturer. This new offering – a combination of software enhancements and Unity Lab Services programs – allows laboratory operators to determine which instruments may be under- …read more
Source: FULL ARTICLE at DailyFinance